Radiopharm Theranostics Limited and GenesisCare have announced a new two-year strategic research collaboration to develop novel radiopharmaceuticals for some complex, hard-to-treat cancers. Through the partnership, Radiopharm Theranostics and GenesisCare will conduct Phase 1 clinical trials in Australia to study the safety and tolerability of novel radiopharmaceuticals, focusing on areas of high unmet need in oncology. As part of the collaboration, GenesisCare's Contract Research Organisation (CRO) and Imaging Research Organisation (IRO), have been engaged to implement three Phase 1 clinical trials in Australia, involving Radiopharm's platform of radiopharmaceutical nanobodies.

Radiopharmaceuticals are designed to deliver small doses of radiation to specifically targeted cells for either therapeutic or diagnostic purposes. Effective cancer radiopharmaceuticals require tumour-specific targets not found in healthy tissue. To date, the majority of clinical developments in radiopharmaceuticals have targeted metastatic prostate cancer and neuroendocrine tumours.

The three Phase 1 clinical trials to be conducted by GenesisCare for Radiopharm under the research partnership are: Phase 1 trial involving Radiopharm's proprietary nanobody from its Nano-mAbs platform which targets the PDL expression in non-small cell lung cancer; Phase 1 trial involving Radiopharm's PTPu targeting peptide in Brain Tumors; and Phase 1 trial involving Radiopharm's PSA targeting antibody which targets free human prostate kallikrein (PSA) in prostate cancer cells.